Payment overview · 2025
General Payments
$876.04
49 reported records · 16 companies
Healthcare provider profile · identity verified
Corey Bryant Chamness, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BROKEN ARROW, OK · NPI 1659714756
Verified facts
What the public records show
CMS Open Payments records show Corey Bryant Chamness, D.O. received $876.04 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 51.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $447.68 | 51.1% | 27 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $68.77 | 7.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.36 | 4.5% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $38.58 | 4.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.56 | 4.4% | 2 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $34.07 | 3.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.76 | 3.7% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $23.76 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.93 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.91 | 2.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.17 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.69 | 2.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.74 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.06 | 2.1% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $15.69 | 1.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.31 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $876.04 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $314.41 | 19 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $68.77 | 4 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $68.77 | 4 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $68.77 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.36 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $12.27 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 119 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 111 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 80 | 44 |
| Gabapentin | Gabapentin | 75 | 22 |
| Lisinopril | Lisinopril | 74 | 35 |
| Losartan Potassium | Losartan Potassium | 66 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 26 |
| Potassium Chloride | Potassium Chloride | 51 | 20 |
| Omeprazole | Omeprazole | 49 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 22 |
| Alprazolam | Alprazolam | 44 | 12 |
| Meloxicam | Meloxicam | 42 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 20 |
| Montelukast Sodium | Montelukast Sodium | 41 | 20 |
| Trazodone Hcl | Trazodone Hcl | 40 | 19 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 32 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Metformin Hcl | Metformin Hcl | 31 | 14 |
| Metformin Hcl Er | Metformin Hcl | 31 | 14 |
| Alendronate Sodium | Alendronate Sodium | 30 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 11 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Furosemide | Furosemide | 26 | 13 |
| Simvastatin | Simvastatin | 24 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $876.04 · 49 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BOTOX, CAPLYTA, COMIRNATY, GLYCATE, LINZESS, MONOFERRIC, MOUNJARO, OTEZLA, PREVNAR 20, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, XIFAXAN, XYOSTED, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error